U.S. Markets closed

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.7600-0.0100 (-0.36%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7700
Open2.8000
Bid2.7200 x 800
Ask2.7700 x 3000
Day's Range2.7350 - 2.8400
52 Week Range0.6900 - 4.2690
Volume316,963
Avg. Volume347,515
Market Cap187.551M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
  • GlobeNewswire

    Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development

    Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments of John Lewicki, PhD, as Chief Scientific Officer, and Ann Kapoun, PhD, as Senior Vice President (SVP) of Translational Research and Development. Drs. Lewicki and Kapoun join Mereo having previously served tenures at OncoMed Pharmaceuticals and were involved in the discovery and development of etigilimab (“Anti-TIGIT”), prior to the 2019 merger of OncoMed and Mereo BioPharma.

  • GlobeNewswire

    Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019

    Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced financial results for the 12 months ended December 31, 2019. “We are very pleased with the substantial operational progress we have made throughout 2019 and particularly, over the past several months,” said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.

  • GlobeNewswire

    Mereo BioPharma Announces Completion of $70 Million Private Placement

    Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) today announces the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based institutional and accredited investors. OrbiMed led the Fundraising with participants including Vivo Capital, Surveyor Capital (a Citadel company), Pontifax Venture Capital, Samsara BioCapital, Commodore Capital, and funds managed by Janus Henderson Investors alongside existing investors Boxer Capital of Tavistock Group and Aspire Capital Fund, LLC. Private placement completed raising $70.0 million (£56.0 million) before expenses.